The QbD column: A QbD factorial experiment

A quick review of QbD The first blog post in this series described Quality by Design (QbD) in the pharmaceutical industry as  a systematic approach for developing drug products and drug manufacturing processes. Under QbD, statistically designed experiments are used to efficiently and effectively investigate how process and product factors […]

Post a Comment

The QbD Column: Overview of Quality by Design

Developing new drugs is a complex, lengthy and expensive endeavor. When the process leads to an approved drug, the result is improved patient care and great benefits for the developers. But many promising drugs never live up to expectations. The US Food and Drug Administration (FDA), observing that new drug […]

Identifying re-enrolled subjects in clinical trials, the sequel

This past June, at the Drug Information Association (DIA) annual meeting, I had the opportunity to present and participate in a panel discussion on innovative approaches to ensure quality and compliance in clinical trials. Not surprisingly, a majority of the discussion focused on sponsor responsibilities for building quality into its […]

Post a Comment

New JMP book on risk-based monitoring & fraud detection in clinical trials

Risk-based monitoring (RBM) is a hot topic in the clinical trials arena. It’s a new way of designing and operating clinical trials. Now, rather than visiting each clinical trial site and reviewing all patient records, you identify just those who present the higher risk of poor data quality, fraud and […]

Post a Comment

Summarizing patient safety with standardized MedDRA queries (SMQs)

If you work or have worked within the pharmaceutical industry, then you are likely familiar with MedDRA, the Medical Dictionary for Regulatory Activities. This dictionary makes it possible for drug and device companies to perform analyses of adverse events or medical history. First, MedDRA provides a way to consistently map […]

Post a Comment

7 things to love about JMP Clinical 5.0

New versions of JMP Clinical and Genomics are available starting today, so I wanted to take the opportunity to give a brief overview of some of the new features you’ll come to enjoy with the new release of JMP Clinical 5.0. Below are seven things to love! 1. Risk-Based Monitoring […]

Post a Comment

Risk-based monitoring: Visualizing the risk to your clinical trials

We’ve talked about the data. We’ve defined our thresholds for risk. Now it’s time to talk about how you can visualize the safety and quality signals from your ongoing clinical trials. If you want to minimize the impact of quality issues to the data or quickly address any safety concerns […]

Post a Comment

Risk-based monitoring: Defining thresholds for risk

Now that we have put together a data set containing the important metrics to monitor safety and site performance, we need to define the thresholds that constitute elevated risk. Unfortunately, there is no one-size-fits all solution to this problem. The study population (e.g., pediatric, elderly or at particular risk of safety […]

Post a Comment

Risk-based monitoring: Let's start with the data

To begin our discussions on risk-based monitoring (RBM), we first need to start with the data. The data include various metrics to assess site performance, and may include several key measures of safety such as deaths and adverse events (to assess safety concerns or under-reporting). But where to start? These […]

Post a Comment

Work smarter, not harder in clinical trials: risk-based monitoring (RBM)

There is a lot of interest in risk-based monitoring (RBM) of clinical trials, and it’s easy to understand why. Monitoring activities can account for 25-30% of the cost of a clinical trial, so any efficiencies to be gained can come at substantial savings for the trial sponsor. ICH Guideline E6 […]

Post a Comment